This is not the latest version of this item. The latest version can be found here.
ACE Inhibitors
| dc.contributor.advisor | Utidjian, Levon |
| dc.contributor.author | Utidjian, Levon |
| dc.contributor.other | Children's Hospital of Philadelphia |
| dc.date.accessioned | 2024-06-10T19:03:21Z |
| dc.date.available | 2024-06-10T19:03:21Z |
| dc.date.created | 2021-11-01 |
| dc.description | This medication concept set includes the following ingredients: Benazepril, Captopril, Enalapril, Fosinopril, Lisinopril, Moexipril, Periondopril, Quinapril,Ramipril, Trandolapril. It also includes combinations of these ingredients with other antihypertensive medications. This code list was generated by taking the descendants of all the ACE inhibitor ingredients of interest and string matching with the concept_name of the ingredient. The broad concept set was intended to identify patients who received ACE inhibitors. It is limited to NDC, RxNorm, and RxNorm Extension codes. Meds were expected to be only oral/enteral/IV, not topical, ophthalmic/ocular, or buccal. |
| dc.description.abstract | Concept set intended to identify patients with an ACE inhibitor medication exposure. |
| dc.identifier.uri | https://pedsnet.org/metadata/handle/20.500.14642/520 |
| dc.language.iso | en-US |
| dc.provenance | Preserving Kidney Function in Children with Chronic Kidney Disease (PRESERVE) |
| dc.publisher | PEDSnet |
| dc.relation.uri | https://atlassian.chop.edu/bitbucket/projects/PR/repos/143_codesets/browse/sql_queries/rx_ace_inhibitor.sql |
| dc.rights | a CC-BY Attribution 4.0 License. |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ |
| dc.subject | Concept Set Development::Content Data Model::PEDSnet Data Model |
| dc.subject | Concept Set Development::Content Data Model::PCORnet Data Model |
| dc.subject | Concept Set Development::Concept Set Evaluation::Clinician Reviewed |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Broad |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Brand Pack Name |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug Form |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug Form |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Ingredient |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Precise Ingredient |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Multiple Ingredients |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Clinical Drug Component |
| dc.subject | Concept Set Development::Concept Set Development Strategy::Medication Characterization::Semantic Branded Drug Component |
| dc.subject.mesh | Angiotensin Converting Enzyme Inhibitor |
| dc.subject.mesh | Protease Inhibitor |
| dc.subject.mesh | Cardiovascular Agent |
| dc.subject.mesh | Enzyme Inhibitor |
| dc.subject.mesh | Antimicrobial |
| dc.subject.other | NDC |
| dc.subject.other | RxNorm |
| dc.subject.other | RxNorm Extension |
| dc.title | ACE Inhibitors |
| dspace.entity.type | ConceptSet |
| relation.isStudyOfConceptSet | 6df51ca1-7a01-4551-b1f1-ca70aaf2c5ae |
Files
Original bundle
1 - 1 of 1